Corporate Research Fronts> Biological Sciences
August 2010
This list of corporate research fronts from Essential Science IndicatorsSM from Thomson Reuters is from the first bimonthly period of 2010, and covers areas in the biological sciences. Source dates are March 31, 2004-February 28, 2010 (sliding 6-year period).
| Research Front Name | % of corp. affiliations | Leading corp. |
|---|---|---|
| METABOLITE IDENTIFICATION LIQUID CHROMATOGRAPHY/HYBRID QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY; EARLY DRUG DISCOVERY HIGH-RESOLUTION LIQUID CHROMATOGRAPHY/QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY | 59 | Waters Corp |
| RECOMBINANT HUMAN APOPTOSIS LIGAND 2/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (RHAPO2L/TRAIL); FULLY HUMAN TRAIL-RECEPTOR 1 MONOCLONAL ANTIBODY | 46 | Genentech, Inc |
| TYPE 2 DIABETES THIAZOLIDINEDIONE MONOTHERAPY; TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED; TYPE 2 DIABETIC PATIENTS | 29 | Merck & Co, Inc |
| DELTA-LIKE 4 NOTCH LIGAND; TUMOR ANGIOGENESIS; BLOCKING NEUROPILIN-2 FUNCTION INHIBITS TUMOR CELL METASTASIS; SENTINEL LYMPH NODES PROMOTES TUMOR METASTASIS | 25 | Regeneron Pharmaceuticals, Inc |
| VIRTUAL SCREENING PROTEIN-LIGAND DOCKING; VIRTUAL SCREENING MULTIPLE BIOACTIVE REFERENCE STRUCTURES; SIMILARITY-BASED VIRTUAL SCREENING 2D FINGERPRINTS | 25 | Schrodinger, LLC |
| PERCUTANEOUS CORONARY INTERVENTION; PROTON PUMP INHIBITORS FOLLOWING ACUTE CORONARY SYNDROME; STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION | 22 | Eli Lilly & Co |
| NONINFLAMMATORY SYNTHETIC SIRNA; POTENT GENE SILENCING IN-VIVO; SYSTEMIC LEUKOCYTE-DIRECTED SIRNA DELIVERY REVEALING CYCLIN D1; POLYETHYLENIMINE (PEI)-COMPLEXED SIRNA IN-VIVO | 20 | Alnylam Pharmaceuticals, Inc |
| 2004-2010_1 | ||
Citing URL: http://sciencewatch.com/dr/crf/2010/10-aug-crf-bio/